Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga’s Edge Stock Rankings, showing remarkable strength and fervor over the past week. 2 Health-Tech Stocks With A Surge In MomentumIn Benzinga’s Edge Rankings, the Momentum score basically indicates the strength of a stock relative to all other stocks ranked. It considers price movements and volatility across multiple time frames, before ranking them individually as a percentile against others.See Also: This Chinese Automa ...

SALT LAKE CITY and BOSTON , Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. ...

SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global ...

Core Insights - SOPHiA GENETICS expands collaboration with AstraZeneca to enhance diagnosis and treatment of breast and prostate cancer through an optimized next generation sequencing (NGS) solution utilizing AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway [1][5] Group 1: Collaboration Details - The partnership aims to improve the detection of genetic mutations linked to cancer development, particularly focusing on the PTEN gene, which when altered, can lead to cancer and treatment resistance [2] - An optimized NGS solution has been developed that employs AI agents to analyze and detect genomic mutations across the full PTEN gene, with a prototype showing improved sensitivity for complex mutations [2][3] Group 2: Implementation and Future Plans - SOPHiA GENETICS will initiate a Privileged Access Program for selected clinical laboratories to validate the sensitivity of the NGS solution in real-world settings, with broader commercial availability anticipated in 2026 [3] - A multi-center real-world evidence study will be conducted to further assess the effectiveness of the solution, aiming to expand patient access to precision therapies through advanced testing in both tissue and liquid biopsy [3] Group 3: Company Mission and Vision - The collaboration reflects the commitment of both companies to drive innovation in precision oncology, ensuring global patient access to advanced genomic testing and targeted treatments [5] - SOPHiA GENETICS emphasizes its mission to democratize data-driven medicine, translating new cancer insights into actionable solutions for patients worldwide [4]

Core Insights - SOPHiA GENETICS has announced a collaboration with Jessa Ziekenhuis to enhance genomic testing and oncology research for cancer patients in Belgium [1][8] - The partnership aims to unify next-generation sequencing (NGS) workflows under a single platform, improving efficiency and compliance with national guidelines [2][5] Group 1: Collaboration Details - Jessa Ziekenhuis processes over 3,000 oncology DNA and RNA samples annually and will implement SOPHiA DDM™ across its pathology operations [2] - The collaboration will involve six SOPHiA GENETICS applications tailored for solid tumors, hematologic malignancies, and liquid biopsy analysis [3] - The integration of SOPHiA GENETICS' cloud-based platform with Jessa Ziekenhuis's Laboratory Information Management System (LIMS) will streamline operations [4] Group 2: Expected Benefits - Jessa Ziekenhuis anticipates a reduction in hands-on time by 30-50% and overall costs by up to 25% through the unified NGS operation [5] - The collaboration will enhance testing turnaround times and improve the scalability of sequencing services [5][6] - The SOPHiA DDM™ Dispatch feature will allow Jessa Ziekenhuis to share a NovaSeq sequencer with AZ Delta, optimizing sequencing capacity and knowledge sharing [6] Group 3: Strategic Importance - The partnership exemplifies SOPHiA GENETICS' commitment to supporting healthcare institutions in scaling genomics capabilities while ensuring quality and efficiency [8] - This collaboration strengthens SOPHiA GENETICS' presence in European hospital networks, promoting data-driven precision medicine [8][9]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $18.3 million, representing a year-over-year growth of 16% compared to $15.8 million in Q2 2024 [35] - Cash burn decreased to $8.7 million in Q2 2025, a 35% year-over-year improvement [42] - Adjusted gross margin improved to 74.4%, up 120 basis points from 73.2% in Q2 2024 [38] Business Line Data and Key Metrics Changes - Revenue excluding biopharma grew 20% year-over-year in Q2 2025, while overall revenue growth was 16% due to modest headwinds from biopharma [19][20] - HemOnc analysis grew 19% year-over-year in Q2 2025, indicating strong performance in hematology testing [21] - Liquid biopsy revenue increased by approximately 900% year-over-year, with 50 customers now using the MSK Access application [72] Market Data and Key Metrics Changes - In North America, revenue excluding biopharma grew more than 19% year-over-year in Q2 2025 [9] - Asia Pacific saw almost 100% year-over-year revenue growth, with significant new business momentum [27] - EMEA growth remained solid, particularly in the UK, which saw over 50% year-over-year volume growth [20] Company Strategy and Development Direction - The company is focused on expanding its customer base, having signed a record 35 new customers in Q2 2025, bringing the total to 63 new customers for the year [8][22] - A major new multi-year partnership with AstraZeneca was announced, focusing on AI-driven predictive models for breast cancer treatment [13][34] - The company aims to optimize cloud compute and storage costs while expanding gross margins beyond 2024 levels [45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, with strong forward-looking indicators such as new business bookings and a robust pipeline [44][48] - The company anticipates that Q4 will be the strongest quarter seasonally, reaffirming full-year revenue guidance of $72 million to $76 million [44] - Management remains focused on achieving adjusted EBITDA breakeven by 2026 and positive adjusted EBITDA by 2027 [42] Other Important Information - The company reported a net dollar retention rate of 107% for the quarter, indicating strong performance in Europe and North America [37] - Total operating expenses for Q2 2025 were $30.8 million, a 19% year-over-year increase primarily due to higher sales and marketing expenses [39][40] - The company has drawn $35 million in debt financing to strengthen its cash position, finishing the quarter with cash and cash equivalents of $94.8 million [43] Q&A Session Summary Question: Can you provide additional details on the AstraZeneca partnership milestones? - Management confirmed that the AstraZeneca deal includes a series of deliverables over several quarters, with confidence in achieving the full value of the contract [52][55] Question: What is the competitive landscape for rare disease applications outside the US? - Management noted that they are seeing strong growth in rare inherited disorders, with a 20% year-over-year increase, and emphasized their competitive positioning in this area [58][61] Question: What prompted the decision to draw the $35 million revolver? - The decision was made to strengthen the cash position in light of accelerating growth across clinical and pharma sides [67][70] Question: What are the adoption trends for MSK Access in the US? - Management reported that liquid biopsy is gaining clinical relevance, with 11 new customers signed for MSK Access in Q2, bringing the total to 50 [72][73] Question: Can you provide insights on the size and structure of the AstraZeneca contract? - Management indicated that the contract includes a mix of base payments and milestone payments, with confidence in recognizing the full value [94][95]

Company Overview - SOPHiA GENETICS' Ai platform SOPHiA DDM™ is used by over 800 healthcare institutions globally to analyze complex health data for cancer and rare disorders[7] - The platform analyzes over 350,000 patients annually and has analyzed over 2 million profiles since its inception[8, 21] - The company has invested over $450 million since its inception in its Ai platform[21, 57] Market Trends - The incidence of cancer and rare disorders is increasing worldwide, driving demand for targeted therapies[13] - Healthcare data is rapidly expanding, with 30% of all data generated globally being healthcare-related[16] - The Total Addressable Market (TAM) for Liquid Biopsy is estimated to be over $5 billion[56] Financial Performance - SOPHiA GENETICS' revenue for 2024 was $65.2 million[60] - The company projects revenue between $72 million and $76 million for 2025, representing a year-over-year growth of approximately 10% to 17%[60, 63] - Adjusted EBITDA loss is projected to be between $35 million and $39 million in 2025, compared to $40.2 million in 2024[63] - The company's adjusted gross margin was 72.8% in 2024 and is expected to expand slightly in 2025[63]

Financial Performance - SOPHiA GENETICS reported Q2 2025 revenue of $18.3 million, reflecting a 16% year-over-year growth [7][12] - Adjusted gross margin improved to 74.4%, up 120 basis points from the previous year [3][12] - The company experienced a net loss of $22.4 million, which is a 48% increase year-over-year [7][12] Business Highlights - The company signed 35 new core genomics customers in Q2 2025, a significant increase from 19 new customers in Q2 2024 [3][8] - A major multi-year AI breast cancer partnership was established with AstraZeneca, marking the largest contract in the company's history [3][12] - The total number of core genomics customers reached 490 as of June 30, 2025, up from 457 at the end of Q2 2024 [8] Operational Efficiency - Cash burn improved by 35% year-over-year, totaling $8.7 million for the quarter [3][7] - The company performed 95,000 analyses on SOPHiA DDMTM, representing a 9% year-over-year volume growth [8] - The partnership with Dasa, the largest medical diagnostics company in Latin America, was expanded to include additional applications [8] Future Outlook - SOPHiA GENETICS reaffirmed its full-year revenue guidance of $72 million to $76 million, indicating a growth of approximately 10% to 17% compared to FY 2024 [12] - The company expects to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027 [12]

Core Insights - SOPHiA GENETICS has expanded its partnership with AstraZeneca to enhance data-driven medicine for breast cancer treatment [1][3] - The collaboration will utilize SOPHiA GENETICS's AI Factories to analyze multimodal healthcare data and generate insights for optimizing treatment outcomes [2][3] Company Overview - SOPHiA GENETICS is a cloud-native healthcare technology company focused on data-driven medicine, particularly in cancer and rare disorders [5] - The company offers the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data to provide actionable insights [5] Partnership Details - The multi-year collaboration aims to develop a bespoke AI-powered predictive model for breast cancer treatment [1][2] - AstraZeneca will leverage SOPHiA GENETICS's AI capabilities to generate real-world evidence and enhance clinical decision-making [2][3] Strategic Importance - This partnership highlights the increasing demand for secure and scalable AI applications in healthcare [3] - The collaboration reinforces SOPHiA GENETICS' position as a trusted technology partner in advancing global health through federated data analytics [3]

Group 1 - SOPHiA GENETICS will release its financial results for Q2 2025 on August 5, 2025, before U.S. markets open [1] - A conference call to discuss the financial results and business outlook will take place at 8:00 a.m. EDT [1] - The call will be webcast live on the SOPHiA GENETICS Investor Relations Website, with a replay available afterward [2] Group 2 - SOPHiA GENETICS is a cloud-native software company focused on data-driven medicine, particularly in cancer and rare disorders [3] - The company developed the SOPHiA DDM™ Platform, which analyzes complex multimodal data to provide actionable insights [3] - SOPHiA GENETICS aims to expand access to data-driven medicine globally through the use of AI [3]